Aptamer-Gold Nanocage Composite for Photoactivated Immunotherapy
Source abstract
Abstract
Immune checkpoint blockade (ICB) has been hailed as the hope for conquering cancer as ICB could produce a significant and durable response to tumor cells. However, the high cost and severe side effects of ICB drugs limited their application for further anticancer therapy. Here, we developed a photoactivated immunotherapy nanoplatform (Apt@AuNC). This nanoplatform could target tumor tissues via enhanced penetration retention (EPR) effect and the aptamer (Apt) could be released from Apt@AuNC in tumor sites via illumination. The immune system in the tumor area was then activated after the combination of Apt and PD-1 protein. The heat generated from AuNC was able to continue killing tumor cells. This nanoplatform could not only achieve the precise immunotherapy but also significantly facilitate the anticancer efficacy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Biology and Medicine, College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei 430081, P.R. China
State Key Laboratory of Biogeology and Environmental Geology, Faculty of Materials Science and Chemistry, China University of Geosciences, Wuhan 430074, P.R. China
Department of Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China
Funding
National Natural Science Foundation of China
References (26)
Show source-provided references
1. 10.1038/s41577-019-0218-410.1038/s41577-019-0218-4 ↗
2. 10.1002/adhm.20180042410.1002/adhm.201800424 ↗
3. 10.1200/JCO.2018.36.15_suppl.307410.1200/JCO.2018.36.15_suppl.3074 ↗
4. 10.1073/pnas.191789111710.1073/pnas.1917891117 ↗
5. 10.1021/acs.accounts.0c0072410.1021/acs.accounts.0c00724 ↗
6. 10.1021/acs.accounts.0c0033910.1021/acs.accounts.0c00339 ↗
7. 10.1021/jacs.1c0201610.1021/jacs.1c02016 ↗
8. 10.1039/D0CC06032A10.1039/D0CC06032A ↗
9. 10.1038/mtna.2015.1110.1038/mtna.2015.11 ↗
10. 10.1021/jacs.2c0401710.1021/jacs.2c04017 ↗
11. 10.1021/acsami.1c1502510.1021/acsami.1c15025 ↗
12. 10.1021/acsnano.7b0911210.1021/acsnano.7b09112 ↗
13. 10.1021/ja504299510.1021/ja5042995 ↗
14. 10.1002/anie.20150918210.1002/anie.201509182 ↗
15. 10.1002/anie.20170333210.1002/anie.201703332 ↗
16. 10.1038/nprot.2007.32610.1038/nprot.2007.326 ↗
17. 10.1021/acs.nanolett.8b0267010.1021/acs.nanolett.8b02670 ↗
18. 10.1021/acsami.0c0559610.1021/acsami.0c05596 ↗
19. 10.1021/acsnano.9b0649210.1021/acsnano.9b06492 ↗
20. 10.1016/j.immuni.2005.10.00510.1016/j.immuni.2005.10.005 ↗
21. 10.1073/pnas.091060910710.1073/pnas.0910609107 ↗
22. 10.1073/pnas.180554211510.1073/pnas.1805542115 ↗
23. 10.1038/onc.2014.28610.1038/onc.2014.286 ↗
24. 10.1002/ptr.535410.1002/ptr.5354 ↗
25. 10.1053/j.seminoncol.2015.05.01510.1053/j.seminoncol.2015.05.015 ↗
26. 10.1136/gutjnl-2016-31158510.1136/gutjnl-2016-311585 ↗